Last reviewed · How we verify

NCT06754358

Clinical Application Comparison of Two Femtosecond Laser Systems

Recruiting now Phase 1 Last updated 31 December 2024
What this trial tests

Phase 1 trial testing LenSx in Cataract in 100 participants. Currently enrolling.

Timeline
29 October 2024
Primary endpoint
31 August 2025
31 October 2025

Quick facts

Lead sponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date29 October 2024
Primary completion31 August 2025
Estimated completion31 October 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

40 and older, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the perioperative parameters of femtosecond laser-assisted cataract surgery (FLACS) using two laser systems. Participants will: Undergo FLACS using LenSx or Z8 femtosecond laser system Visit the clinic before the operation and 1 day, 1 week, and 1 month after the operation for checkups and tests Complete clinical measurements and dry eye questionnaires

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of LenSx

Trials testing the same drug.

Other recruiting trials for Cataract

Currently open trials in the same condition.

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06754358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing